Skip to main content

Events

Upcoming events

Past events

14 Nov 2023
Vaccinal effect of monoclonal antibodies: A Vaccine Enterprise timely topics roundtable
The roundtable will bring together HIV vaccine R&D leaders to review knowledge of the vaccinal effect and discuss its relevance in the anti-HIV immune response and design of preventive and curative vaccine strategies. View details View details
16 Oct 2023
HIVR4P symposia series - The future of bNAbs
Join us this October 2023 for a virtual symposia series exploring the latest HIV prevention research. What role can bNAbs play in HIV cure research? View details View details
11 Oct 2023
HIVR4P symposia series - Insights in HIV vaccine research
Join us this October 2023 for a virtual symposia series exploring the latest HIV prevention research. What are the latest developments in the quest for an effective HIV vaccine? View details View details
4 Oct 2023
HIVR4P symposia series - Implementation and rolling out of CAB-LA
Join us this October 2023 for a virtual symposia series exploring the latest HIV prevention research. How do you scale up use of CAB-LA and the vaginal ring? View details View details
23 Jul 2023
The 12th IAS Conference on HIV Science

IAS 2023, the 12th IAS Conference on HIV Science, will take place in Brisbane, Australia, and virtually from 23 to 26 July 2023. IAS 2023, being held at the Brisbane Convention and Exhibition Centre, will shine a spotlight on the world’s advances in HIV research.

View details View details
22 Jul 2023
2023 HIV Cure & Immunotherapy Forum

The 2023 HIV Cure & Immunotherapy Forum, organized by the IAS Towards an HIV Cure initiative, will be held at the Brisbane Convention & Exhibition Centre in Brisbane, Australia, on 22 July 2023 alongside IAS 2023, the 12th IAS Conference on HIV Science. The content of the Forum will be accessible online after the meeting.  

View details View details

The IAS promotes the use of non-stigmatizing, people-first language. The translations are all automated in the interest of making our content as widely accessible as possible. Regretfully, they may not always adhere to the people-first language of the original version.